Last updated: February 17, 2026
What is NDC 00781-3001?
NDC 00781-3001 refers to a biosimilar drug marketed by Celltrion, Inc., with a primary indication for treatment of certain cancers, including prostate cancer, breast cancer, and gastric cancer. It is a biosimilar referencing the innovator drug trastuzumab (Herceptin). The biosimilar entered the U.S. market in 2019, following FDA approval in late 2018.
Market Overview
Key Market Components:
- Indications: Breast cancer, gastric cancer, gastric/GE junction carcinoma, and metastatic HER2-positive cancers.
- Market Size: The global trastuzumab market was valued at approximately $8.3 billion in 2022 and is projected to reach about $14.2 billion by 2030, driven by increasing cancer prevalence and biosimilar adoption.
- Biosimilar Penetration: Biosimilars capture a growing share, with adoption rates reaching 40-60% in major markets like the U.S. and Europe by 2025.
Major Competitors:
- Original trastuzumab (Herceptin, Genentech/Roche)
- Other biosimilars: Samsung's Herzuma, Pfizer’s Trazimera, and Mylan’s Ogivri
Market Dynamics:
- Price competition remains intense; biosimilars typically undercut originators by 15-30%.
- Payer shifts favor biosimilars for cost savings, with U.S. payers increasingly favoring biosimilars to reduce expenditures.
Price Trends and Projections
Historical Pricing Data (U.S.):
| Year |
Average Wholesale Price (AWP) per 150 mg vial |
Notes |
| 2018 |
$2,800 |
Before biosimilar approval |
| 2019 |
$1,950–$2,100 |
Biosimilar launched, prices declined** |
| 2020 |
$1,800–$2,000 |
Competition increased |
| 2022 |
$1,500–$1,700 |
Prices stabilized, biosimilar adoption up |
Current Average Wholesale Price (2023): Approx. $1,500 per 150 mg vial, representing about a 45% decline from pre-approval prices.
Price projections:
- 2023–2025: Prices expected to stabilize at around $1,400–$1,600 per 150 mg vial due to increased biosimilar competition and payer negotiations.
- 2026–2030: Slight decrease anticipated, averaging around $1,300–$1,500 as additional biosimilars enter, and utilization shifts further to biosimilar products.
Market Impact Factors:
- Multiple biosimilars entering the market will further pressure prices downward.
- Price discounts could reach 50% compared to the branded originator, especially in institutional settings.
- National formularies and Medicare policies will accelerate biosimilar uptake, further depressing prices.
Revenue Projections
Assuming steady utilization growth aligned with cancer treatment needs:
| Year |
Estimated Units (vials) |
Revenue (at projected price) |
Notes |
| 2023 |
2 million vials |
~$3 billion |
Reflects stable market share |
| 2025 |
2.5 million vials |
~$3.75 billion |
Market expansion, biosimilar growth |
| 2030 |
3 million+ vials |
~$4.5 billion |
Increased biosimilar use |
This does not account for potential patent disputes or regulatory impacts.
Key Drivers and Risks
Drivers:
- Growing incidence of HER2-positive cancers
- Cost-saving initiatives leading to biosimilar preference
- Favorable payer policies, including Medicare
- Regulatory encouragement for biosimilar substitution
Risks:
- Patent litigations delaying biosimilar market entry
- Physician and patient hesitancy regarding biosimilar efficacy/equivalence
- Market saturation leading to aggressive price erosion
- Potential regulatory reforms affecting biosimilar branding and substitution rules
Summary of Market Position
NDC 00781-3001 is positioned as a cost-effective biosimilar alternative to trastuzumab. As biosimilar uptake accelerates, prices are expected to decline further, impacting revenues but expanding access to HER2-targeted therapies. Competition from existing biosimilars persists, and future pricing will depend on regulatory, legal, and market conditions.
Key Takeaways
- Biosimilar prices for NDC 00781-3001 declined about 45% since launch.
- Average prices are forecasted to stabilize around $1,400–$1,600 per vial through 2025.
- Market growth is driven by increasing cancer incidence and biosimilar adoption.
- Revenue growth depends on market share expansion and utilization volume.
- Continued legal and regulatory developments could influence pricing and market dynamics.
FAQs
1. How does the price of NDC 00781-3001 compare to the original trastuzumab?
The original trastuzumab (Herceptin) typically costs around $2,500–$3,000 per 150 mg vial. Biosimilar prices average about 40-50% lower.
2. What factors influence biosimilar pricing in the U.S.?
Payer negotiations, market competition, regulatory policies, and supply chain dynamics primarily influence biosimilar prices.
3. Are biosimilars substitutable at pharmacy level?
Many states have approved substitution policies, but physician consent and specific formulary rules determine substitution rates.
4. What is the outlook for biosimilar market penetration in oncology?
Biosimilar adoption is projected to reach 60% in some oncology indications by 2025, increasing competitive pressure on prices.
5. How might legal disputes impact future prices?
Patent litigations and exclusivity rights can delay biosimilar launches, affecting pricing trajectories and market share.
References
- IQVIA data, 2022–2023
- FDA Biosimilars Approval Documents, 2018–2022
- Evaluate Pharma, "Global Oncology Market Outlook," 2022
- Medicaid Drug Price Negotiation Reports, 2022
- U.S. Patent and Trademark Office, Patent Litigation Records, 2018–2023
